We investigated a family in which some individuals showed extremely high serum leucine aminopeptidase (LAP) (EC 3.4.11.2) activity, mainly derived from a variant CD13. The isoelectric points of the variant and normal CD13 were 3.3 and 4.1, respectively, and both points converged at 4.4 after treatment with neuraminidase, indicating that more sialic acids are bound to the variant CD13 than normal. The molecular masses of both CD13s were 144 kDa by sodium dodecyl sulfatepolyacrylamide gel electrophoresis. After treatment with neuraminidase, N-glycosidase, and O-glycosidase, apparent molecular masses of the variant and normal CD13 were 106 kDa and 100 kDa, respectively, suggesting that the variant CD13 contains a longer peptide than normal. This is the first case of familial high serum LAP activity in which the origin could be demonstrated by anti-CD13 monoclonal antibodies to be a variant CD13 inherited in an autosomal dominant mode. The isoelectric point of the LAP activity after neuraminidase treatment was different from that previously reported.
attack the same substrate. For example, cystine aminopeptidase (EC 3.2.11.3), which increases in sera of pregnant women, also cleaves l-leucine-p-nitroanilide. For this reason, applying specific monoclonal antibodies may be useful in a study to clarify to what extent a particular enzyme contributes to serum LAP activity.
LAP is located in various tissues including the small intestine, renal proximal tubules, and the canalicular domain of hepatic cell membranes. The cDNA of an enzyme with aminopeptidase activity has been cloned and found to be identical to CD13, a cell surface marker of granulocytes, monocytes, and their progenitors [1] [2] [3] [4] . The results of a previous study involving an inhibition assay with specific monoclonal anti-CD13 antibodies [3, 5] demonstrated that aminopeptidase activity in sera from healthy individuals and patients with hepatobiliary disorders is predominantly attributable to CD13 [6] . No report, however, has demonstrated the contribution of CD13 to familial high serum aminopeptidase activity.
We investigated a family in which three of five members showed extremely high serum LAP activity in spite of their not having any other physical or laboratory abnormality. Using anti-CD13 monoclonal antibodies, we discovered that this activity was mainly due to a novel variant CD13.
Although in the US and in European countries serum aminopeptidase (EC 3.4.11.2) is often called AAP, in our country it is conventionally measured as LAP, with lleucine-p-nitroanilide as a substrate. Because this example of familial high serum aminopeptidase was discovered by measurement of LAP activity and also by electrophoresis, in which it was detected with l-leucine-␤-naphthylamide, we thus use LAP in this communication.
Patient and Methods
The propositus, a 34-year-old woman, visited our hospital because her high serum LAP activity had been noted when she went to a gynecological clinic for treatment of endometriosis. She had had no particular disease other than endometriosis and showed no particular abnormality in the physical findings or the routine laboratory examination except for the high serum LAP activity. Chest x-ray film, electrocadiography, abdominal ultrasonography, and abdominal computed tomography revealed no abnormalities. She had no symptom suggesting the immunological dysfunction of leukocytes.
Serum samples were collected from the propositus, her father, mother, paternal grandmother, and younger sister, none of whom had any particular disease, and an unrelated healthy volunteer (a 37-year-old man) as a control. The procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 1983, and with the ethical standards for research of our university. measurement of serum lap activity LAP activity was measured by a Model 736 automated analyzer (Hitachi) with reagents LAP-HR (Wako Pure Chemical Industries): l-Leucine-p-nitroanilide was used as a substrate and absorbances at 415 nm (main) and 505 nm (sub) were monitored to measure the production of p-nitroaniline at 37°C in 80 mmol/L Tris-HCl buffer, pH 7.4. The enzyme activity was expressed as U/L, where 1 U represents the activity required to generate 1 mol of p-nitroaniline per minute. The reference interval was 33-73 U/L, and the upper detection limit was 700 U/L. Serum samples that showed higher LAP activities than this limit were remeasured after appropriate dilution.
high-voltage isoelectric focusing on cellulose acetate membranes Serum, 5 L, or partially purified CD13 was analyzed by high-voltage isoelectric focusing. This was performed according to a method developed in our laboratory that involves laying a maximum of six sheets of cellulose acetate membranes Separax-EF (Fuji Photo Film) on top of each other for simultaneous electrophoresis, resulting in six copies of the identical electrophoretic pattern [7, 8] . In this study, three sheets of cellulose acetate membranes that had absorbed 100 g/L ampholyte Sepaline (pH 3.5-10) (Fuji Photo Film) and 100 g/L sucrose were used simultaneously. After electrophoresis, one sheet was used for protein staining with Coomassie Brilliant Blue G-250, one for LAP activity staining, and one for immunoblotting.
lap-activity staining of cellulose acetate membranes
The cellulose acetate membrane after isoelectric focusing was incubated at 37°C for 15-30 min in a solution containing 0.55 mmol/L l-leucine-␤-naphthylamide (Sigma), 0.84 mmol/L Fast-Garnet (Sigma), 0.65 mmol/L magnesium sulfate, and 32 mmol/L sodium phosphate (pH 6.6).
immunoblotting with anti-cd13 antibodies sodium dodecyl sulfate-polyacrylamide gel electrophoresis (sds-page) SDS-PAGE was performed on a 75 g/L polyacrylamide separating gel according to Laemmli's procedure [9] . Protein staining was carried out with Coomassie Brilliant Blue R-250 or Silver Stain II Kit (Wako Pure Chemical).
partial purification of serum cd13 by deae cellulose ion-exchange column chromatography immunoprecipitation of serum cd13 Serum, 100 L, or partially purified CD13 was mixed with 15 L of MCS-2 (100 mg/L) and incubated for 2 h at 4°C; then 2 L of rabbit anti-mouse IgG ␥-globulin (28.7 g/L) was added and the mixture was incubated overnight at 4°C. After centrifugation at 7000g for 5 min, the precipitate was washed twice with TBS containing 1 mL/L Triton X-100 and once with TBS, then subjected to SDS-PAGE or measurement of LAP activity. Heat-inactivated MCS-2 (98°C, 1 min) or normal mouse IgG was used as a control. To measure LAP activity in the immunoprecipitate, it was redissolved in 50 mmol/L glycine-HCl buffer, pH 2.5, and applied to the method described above, where pH of the applied sample was adjusted to 7.4 by dilution with LAP-HR buffer solution.
purification of cd13
After immunoprecipitation and SDS-PAGE, CD13 was eluted from the excised gel piece by overnight shaking in 200 L of 20 mmol/L Tris buffer containing 10 g/L SDS (pH 8.0) at 4°C. Cold (4°C) acetone, 1 mL, and 5 g of glycogen were added to the eluate and left for 1 h at Ϫ80°C. The precipitate was dried and dissolved in 10 L of 20 mmol/L sodium phosphate, pH 7.4, containing 10 mL/L Nonidet P-40 and 1 g/L SDS. treatment with neuraminidase, n-glycosidase, and o-glycosidase One hundred microliters of serum or partially purified CD13 was incubated with 10 L of neuraminidase (III) (NRH-301, Toyobo) in piperazine-N,NЈ-bis-(2-ethanesulfonic acid) (PIPES) buffer, pH 6.5 (10 U/L neuraminidase, 10 mmol/L PIPES) for 2 h at 37°C.
Purified CD13 was treated with N-glycosidase F (0.5 U/L) (Boehringer Mannheim) and (or) bovine serum albumin-free O-glycosidase (0.2 U/L) (Boehringer Mannheim) in 20 mmol/L sodium phosphate buffer, pH 7.4, containing 10 mL/L Nonidet-P40 and 1 g/L SDS, overnight at 37°C.
Results

lap activity in serum
Because a serum sample of the propositus diluted at 1:5 with PBS showed 449 U/L of LAP activity, which was within the measuring range (Ͻ700 U/L), we determined her serum LAP activity as 2245 U/L, 31 times higher than the normal upper limit (73 U/L). Likewise, the LAP activities of her father and paternal grandmother were determined as 1860 U/L and 1980 U/L, respectively. On the other hand, her mother and younger sister showed normal serum LAP activity (Fig. 1) .
immunoprecipitation of serum cd13
Serum samples of the propositus containing 54.4 mU of LAP activity each were subjected to immunoprecipitation with an anti-CD13 monoclonal antibody MCS-2 or a control IgG. As shown in Table 1 , 71% of the activity was removed from the serum and 45% of the removed activity was recovered in the precipitate. In contrast, heat-inactivated MCS-2 or normal mouse IgG did not precipitate LAP activity in the sample. These results proved that the high LAP activity in the serum of the propositus is predominantly due to CD13.
isoelectric point of cd13
After isoelectric focusing, immunoblotting of the cellulose acetate membrane with anti-CD13 monoclonal antibody MCS-2 revealed a protein at pI 4.1 in the sera with normal LAP activities (from the mother, younger sister, and unrelated control). In contrast, MCS-2 revealed an additional band at pI 3.3 in sera with unusually high LAP activities from the propositus, her father, and her grandmother. Reactivity to this abnormal band was higher than that to the normal band at pI 4.1 in these samples ( Fig.  2A) . Another anti-CD13 antibody, B-F10, also gave a similar result (data not shown). LAP activity could be detected only at pI 3.3. The enzyme activity at pI 4.1 in the sera with high LAP activity as well as normal samples was less than the sensitivity of the assay condition (Fig.  2B) . These results indicate that the abnormally high LAP activity is mainly derived from a variant CD13 with pI 3.3.
To characterize this variant CD13, we tested the effect of neuraminidase treatment of the sera on the isoelectric points. Interestingly, both the normal and variant CD13 showed pI 4.4 after treatment with neuraminidase (Fig.  3A) . This suggests that the variant CD13 contains more sialic acids than normal. Even after the pI shift, the variant CD13 still maintained high LAP activity (Fig. 3B ).
molecular mass of cd13
To determine the molecular mass of CD13, serum samples were subjected to immunoprecipitation followed by SDS-PAGE. In serum from a healthy volunteer, a 144 kDaprotein was precipitated by MCS-2 but not by normal mouse IgG (Fig. 4A) . Immunoprecipitation of serum from the propositus also showed a single band at the slightly larger position than normal, although the difference was subtle in this assay condition. After treatment with neuraminidase, the molecular mass of the normal CD13 diminished to 132 kDa, and the variant CD13 looked only slightly larger than normal (Fig. 4B) .
effects of n-glycosidase and o-glycosidase
Before the treatments with N-glycosidase and (or) Oglycosidase, a serum sample of the propositus and a partially purified normal CD13 sample were first treated with neuraminidase, immunoprecipitated, and further purified from the protein band excised from the SDS-PAGE gel. Being incubated with both N-glycosidase and 
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O-glycosidase simultaneously, purified normal and the variant CD13 showed molecular masses of 100 kDa and 106 kDa, respectively (Fig. 5 ). Even treatment with Nglycosidase alone gave a similar result, whereas treatment with O-glycosidase alone had no effect on the molecular masses of CD13. These results suggest that the peptide of the variant CD13 is larger than normal and, in addition, virtually all carbohydrate chains of CD13 are covalently bound by N-glycosidic linkages.
Discussion
It might be interesting to test the cell surface LAP activity of the propositus because CD13 is a molecule originally defined as a marker of granulocyte-monocyte lineage, but the current study focused on analysis of the serum CD13 that showed extraordinarily high LAP activity by a conventional laboratory test.
The removal of 71% of LAP activity from the serum sample of the propositus by immunoprecipitation with an anti-CD13 monoclonal antibody and demonstration of the activity in the precipitate proved that high serum LAP activity of the propositus is predominantly due to CD13. This percentage is consistent with the report in which 60% to 80% of serum aminopeptidase activity was shown to be ascribed to CD13 in healthy individuals and patients with hepatobiliary disorders [6] .
High-voltage isoelectric focusing followed by reaction with anti-CD13 monoclonal antibodies revealed that the -3) , whereas normal LAP activities were less than the sensitivity of this assay (lanes 4 -6). Fig. 3 . Effect of neuraminidase on isoelectric points.
Partially purified serum CD13 from the propositus (P) and a healthy volunteer (N) were treated (lanes 3 and 4) or untreated (lanes 1 and 2) with neuraminidase. After high-voltage isoelectric focusing, the cellulose acetate membranes were reacted with MCS-2 (A) or incubated with L-leucine-␤-naphthylamide (B).
isoelectric point of normal serum CD13 was 4.1. Only in the sera from family members with high LAP activity did we find a variant CD13, as a band with an abnormally low isoelectric point (pI 3.3), that was recognized with the two anti-CD13 monoclonal antibodies. The abnormal band showed extremely high enzyme activity by incubation with l-leucine-␤-naphthylamide, whereas the normal LAP activity that should be stained at pI 4.1 was much lower and hardly visualized. Thus the variant CD13 is considered to be the principal contributor to the unusually high serum LAP activity in this family case study. The variant CD13 in this case was inherited from the paternal grandmother of the propositus through the father to the propositus but was not passed on to her sister, and all members of the family, including the above members with the variant CD13, also had normal CD13 in their sera. Therefore the mode of inheritance is autosomal dominant and the members with high LAP activity in this family are heterozygotes of the variant and normal genes. By treatment with neuraminidase, the isoelectric points of both normal and the variant CD13 became identical at pI 4.4, indicating that more sialic acids are bound to the variant CD13 molecule than to normal. The extra sialic acids of the variant CD13 may retard its turnover rate in serum, resulting in high serum LAP activity. In fact, a report compatible with this hypothesis has shown that desialylated serum glycoproteins have drastically reduced their survival times in the circulation [10] .
From a search of the English literature, we found only one report of a family with high serum aminopeptidase activity [11, 12] . However, in that case, the isoelectric point of the aminopeptidase of the propositus remained lower than normal even after treatment with neuraminidase, and it remained unclear whether the high serum aminopeptidase activity was derived from serum CD13 or from other enzymes.
CD13 is a glycoprotein with a molecular mass of 150 kDa, the peptide portion of which is 110 kDa [1] . The deduced amino acid sequence of normal CD13 predicts 10 possible Asn-X-Ser/Thr N-glycosylation sites [3] , and several O-glycosylation sites have also been suggested [13] .
Glycoprotein molecular mass measurement by SDS-PAGE ought to be the most accurate when the carbohydrate chains are completely removed [14] . In our results, the combined treatment with neuraminidase, N-glycosidase, and O-glycosidase decreased the molecular masses of CD13s, and the decreased size of the variant (106 kDa) was larger than normal (100 kDa). However, O-glycosidase alone caused no significant change in the size of CD13 treated with neuraminidase. These results suggest that the peptide of variant CD13 is longer than normal and virtually all of the carbohydrate chains are covalently bound to CD13 by N-glycosidic linkages. The extra portion of the peptide of the variant CD13 may contain extra glycosylation sites for carbohydrate chains, which would allow more addition of sialic acids to the variant CD13, explaining its lower isoelectric point.
The molecular masses of both normal (100 kDa) and the variant CD13 peptides (106 kDa) in serum seemed to be smaller than the reported molecular mass of CD13 peptide (110 kDa) directly extracted from cultured cells [1] . Thus the peptides may be posttranslationally modified during or after the process of release from cell membrane into serum.
In conclusion, the high serum LAP activity in this family case is derived from a novel variant CD13 inherited in an autosomal dominant mode. The variant contains more sialic acids and is suggested to have a larger peptide than normal. Whether this variant is the product of a mutated CD13 gene or an abnormal modification after translation remains unknown. To elucidate the molecular mechanism that produces this variant, we are currently working to determine the cDNA sequence of this CD13 and the amino acid sequences of its N-and C-terminal portions.
